Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464555 | 0.86 | KMT2A (0.31) | KMT2AATM | |
| SCHEMBL7431766 | 0.72 | POLB (0.31) | KMT2AATM | |
| Ethylene Glycol SCHEMBL3801456 | 0.68 | POLB (0.31) | — | |
| SCHEMBL7209074 | 0.68 | POLB (0.35) | — | |
| SCHEMBL913291 | 0.66 | POLB (0.34) | — | |
| SCHEMBL4942646 | 0.66 | LMNA (0.33) | KMT2A | |
| SCHEMBL30080738 | 0.65 | KMT2A (0.32) | KMT2A | |
| SCHEMBL4001225 | 0.64 | MAPT (0.35) | KMT2A | |
| SCHEMBL3938392 | 0.64 | RIPK1 (0.34) | — | |
| SCHEMBL6517344 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497437-B2 | Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseases | THE GENERAL HOSPITAL CORPORATION | 2025-12-16 | — | — | US | disclosed |
| US-12208143-B2 | Compositions and methods for transport across the blood brain barrier | OPHIDION INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12139542-B2 | Inhibitors of aortic carboxypeptidase-like protein (ACLP) | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240277812-A1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-22 | — | — | US | disclosed |
| US-11998590-B2 | Use of Mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation | THE GENERAL HOSPITAL CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-20220387612-A1 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER | OPHIDION INC. | 2022-12-08 | — | — | US | disclosed |
| US-11376331-B2 | Compositions and methods for transport across the blood brain barrier | OPHIDION INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-4008339-A1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION | The General Hospital Corporation (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3079712-B1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | MASSACHUSETTS GEN HOSPITAL (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11135269-B2 | Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation | THE GENERAL HOSPITAL CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| EP-1198256-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6339069-B1 | ADMINISTERING FORMULATION COMPRISING PHARMACEUTICALLY ACCEPTABLE CARRIER; AND, LIPOSOME COMPRISING A BIOACTIVE AGENT AND A LIPID COMPONENT, THE LIPID COMPONENT COMPRISING A PEPTIDE-LIPID CONJUGATE | ELAN PHARMACEUTICALSTECHNOLOGIES, INC. | 2002-01-15 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001000247-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6143716-A | CONTROLLED DELIVERY SYSTEM TO DELIVER LIPOSOMAL DRUGS IN VITRO OR IN VIVO, FOR EXAMPLE, IN TREATMENT OF MAMMALS AFFLICTED WITH VARIOUS DISEASES, DISORDERS OR CONDITIONS, E.G., CANCERS | THE LIPOSOME COMPANY, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6087325-A | CONJUGATE OF CERTAIN PEPTIDES TO PHOSPHATIDYLETHANOLAMINES, INCORPORATED INTO LIPOSOMES SO AS TO SELECTIVELY DESTABILIZE THE LIPOSOMES IN THE VICINITY OF TARGET PEPTIDASE-SECRETING CELLS, HENCE DELIVER THE LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0964690-A4 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CO INC (US) | 2000-03-29 | — | — | EP | disclosed |
| EP-0964690-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998016240-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | KMT2A 3287/4885ATM 4090/4885 |
| US-12139542-B2 | Inhibitors of aortic carboxypeptidase-like protein (ACLP) | ENPEP, ADAM8, ADAM17 | KMT2A 3964/4885ATM 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.